Rapidly expanding research has identified a growing number of aging-related chronic conditions that cannabis can treat. That’s both the result of record levels of investment – and an indicator of future growth, said Pavel Kubu, M.D., Founder & CEO of the Prague-based International Cannabis and Cannabinoid Institute (ICCI).
“Both business and government realize that this thriving industry has a future but the development must be based on conclusive research,” Kubu said.
Kubu will discuss that topic as one of the featured speakers at “The Future of Medical Hemp,” the next networking & intelligence event in HempToday’s annual Summit Series devoted to industrial hemp. Only 8 accreditations remain for the Aug. 24-25 gathering at HempToday Center in Poland; the summit is limited to 25 participants total. The application period remains open through Aug. 15.
Vast European market
Europe’s market of over 739 million people is poised to be the largest medical cannabis market in the world, Kubu noted.
As research continues apace, ongoing discovery is sure to address further chronic conditions of aging that may be treatable by cannabis, Kubu said. “As the list grows, so does the potential patient base,” he noted.
And critical to serving the aging EU population, as new treatments are developed, is efficient delivery, Kubu added.
Personalized treatment needed
“Clinical experience and initial evidence indicate the need for personalization of cannabis treatment with digital tools to provide efficient cures, while keeping the quality of life on an ambient level,” he said.
ICCI advances quality standards and addresses a wide range of issues related to cannabis and CBD. Kubu is also chairman of the Ethical Commission at the Czech National Monitoring Center for Drugs and Drug Abuse, and a founding member of the International Medical Cannabis Patient Coalition.
